CorePlus Pioneers AI-Powered Cervical Cancer Screening in Puerto Rico

CorePlus, a precision pathology organization, has successfully operationalized the Techcyte AI algorithm for cervical cancer screening in Puerto Rico, achieving 100% quality control of Pap tests and promoting patient safety, with significant implications for women's health globally. The milestone marks a new standard for cervical cancer screening, particularly in underserved populations, and highlights the importance of ethnic diversity in eliminating algorithmic bias." This description focuses on the primary topic of the article (CorePlus' operationalization of the Techcyte AI algorithm for cervical cancer screening), the main entities involved (CorePlus, Techcyte, and Puerto Rico), the context of the event (cervical cancer screening in Puerto Rico), and the significant actions and implications of the story (achieving 100% quality control, promoting patient safety, and eliminating algorithmic bias). The description also provides objective and relevant details that will help an AI generate an accurate visual representation of the article's content.

author-image
Trim Correspondents
New Update
CorePlus Pioneers AI-Powered Cervical Cancer Screening in Puerto Rico

CorePlus Pioneers AI-Powered Cervical Cancer Screening in Puerto Rico

CorePlus, a precision pathology organization, has become the first laboratory worldwide to operationalize the Techcyte AI algorithm and quality control workflow for cytology-based cervical cancer screening. This groundbreaking achievement, taking place in Carolina, Puerto Rico, ensures 100% quality control of all Pap tests, surpassing regulatory mandates.

Why this matters: This development has significant implications for women's health globally, as it sets a new standard for cervical cancer screening and has the potential to reduce the incidence of cervical cancer in underserved populations. Early detection and accurate diagnosis can lead to better treatment outcomes, improved quality of life, and reduced healthcare costs.

The milestone comes after more than two years of clinical collaboration between CorePlus and Techcyte. The validation study, conducted by Dr. María del Mar Rivera-Rolón, CorePlus' Board-Certified Cytopathologist, included the digitization of over 1,500 cases scanned on the Epredia P1000 with water immersion at different modalities.

The inclusion of Puerto Rican women in the algorithm's validation holds great significance, as ethnic diversity is crucial for eliminating potential algorithmic bias. Mariano de Socarraz, Founder and CEO of CorePlus, emphasized, "We are fortunate to have been able to include Puerto Rican women in the validation of the algorithm. Ethnic diversity is a key to eliminating potential algorithmic bias. Including this subset of the population ensures that Hispanic women will be well represented."

The importance of early detection cannot be overstated, as Puerto Rican women faced an increase in the cervical cancer incidence rate from 9.2 to 13 cases per 100,000 between 2001 and 2017. Early detection is paramount for providing initial therapeutic intervention, ensuring better quality of life, and impacting healthcare costs.

CorePlus will now review 100% of Pap tests processed at their laboratory using the Techcyte AI-assisted tool, aiming to deliver more accurate results and promote patient safety. Juan C. Santa-Rosario, M.D., CorePlus' Chief Medical Officer, stated, "Our validation study... was conducted by Dr. María del Mar Rivera-Rolón, our Board-Certified Cytopathologist. Now we will be able to review 100% of Pap tests processed at our laboratory using the Techcyte AI-assisted tool with the intent of providing more accurate results and promoting patient safety."

Ben Cahoon, CEO of Techcyte, praised CorePlus' innovative approach, saying, "CorePlus is one of the most innovative organizations in the world at implementing digital pathology solutions. We are thrilled they will be using our AI-based cervical cytology software to have a real impact on the health of women in Puerto Rico and throughout the world."

CorePlus, a high-complexity CLIA-certified laboratory with facilities in Carolina and Ponce, Puerto Rico, has been at the forefront of transforming pathology through digital pathology and AI algorithms since 2020. Techcyte, founded in 2013, is revolutionizing the practice of pathology with a unified platform that digitizes lab workflows and offers AI tools to improve the efficiency and accuracy of diagnostic testing. Epredia, a global leader in precision cancer diagnostics, provides a unique array of end-to-end instruments for pathology workflows.

The successful operationalization of the Techcyte AI algorithm by CorePlus marks a significant step forward in cervical cancer screening. By achieving 100% quality control of Pap tests and promoting patient safety, this groundbreaking development holds the potential to positively impact the lives of women in Puerto Rico and beyond.

Key Takeaways

  • CorePlus becomes first lab to operationalize Techcyte AI algorithm for cervical cancer screening.
  • 100% quality control of Pap tests achieved, surpassing regulatory mandates.
  • Inclusion of Puerto Rican women in algorithm validation ensures ethnic diversity.
  • Early detection crucial for cervical cancer treatment and reduced healthcare costs.
  • CorePlus to review 100% of Pap tests using Techcyte AI-assisted tool for accurate results.